Zimbabwe has rejected a major American healthcare agreement worth 367 million US dollars (272 million pounds) over five years because of Washington's demand for confidential data.
This move became public after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official spokesperson has since clarified that the US was seeking health data for scientific study and commercial purposes while was unwilling to share the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued talks to reach a agreement acceptable to both sides so the country's critical HIV programme can proceed.
Wider Context
This development follows a comparable case in neighbouring Kenya, where a court suspended a related health funding agreement following concerns were raised about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to enhance transparency and responsibility.
As per reports, Sixteen African countries have so far agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment through US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information for a long time, without any equivalent assurance of access to any medical innovations – such as new medicines or tests – that could be developed from that shared data," he stated.
"In essence, our country would supply the raw materials for medical research without any assurance that the final treatments would be accessible to our citizens if a new pandemic arise."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of one-on-one deals were upending frameworks previously set up via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing framework designed to manage potential global health emergencies.
"This system is intended to ensure that when a nation provides its information, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the resources to develop them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to further discussions with our American counterparts on how subsequent co-operation could be designed in a manner that honours the independence and interests of both nations."
Health Experts Response
A leading public health body said it recognised the government's concerns, but suggested that talks must proceed given that much of the country's Aids initiatives depended on international support.
"In cases where specific concerns arise, such as those relating to data governance or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," it commented.
The situation underscores the ongoing challenges between accepting vital foreign assistance and safeguarding local interests in an ever more interconnected world.